UserTesting Welcomes Two New Members to Its Board of Directors
4.3.2021 14:00:00 EET | Business Wire | Press release
UserTesting, a leading provider of on-demand human insights, today announced the addition of two new members to the board of directors with the election of Shannon Nash, and Cindy Russo, who will serve as the audit chair. These two women bring a wealth of financial and operational experience as UserTesting continues to expand and diversify the board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005388/en/
UserTesting Welcomes Two New Members to Its Board of Directors (Graphic: Business Wire)
Nash brings more than two decades of experience to the board, and is currently the Chief Accounting Officer at Reputation, the global leader in reputation experience management. Previously, Nash held executive finance roles at Insidesource, Cumulus Media Inc. (NASDAQ: CMLS), Aspire Public Schools, and Sunseeker Media. She is also a board member of the Silicon Valley Community Foundation and on the CalCPA Diversity Equity & Inclusion Commission.
“UserTesting and Reputation both understand the important role customer feedback plays in building strong brands, products, and services,” said Nash. “I immediately recognized this as a great opportunity as I see companies struggling to mobilize the voice of their customer everyday, and I know UserTesting is a critical component of helping companies make smarter, customer-informed decisions. I look forward to working with and providing guidance for UserTesting, to ensure they successfully grow and scale, globally.”
Russo is currently a board member at Par Technology Corp (NYSE: PAR) and Verra Mobility Corp (NASDAQ: VRRM), where she is a member of the audit committees and compensation committees. She most recently served as Executive Vice President and Chief Financial Officer of Cvent, Inc., a cloud-based enterprise event management platform. Prior to that, Russo held several finance-related roles at MICROS Systems, Inc., where she was Executive Vice President and Chief Financial Officer through the acquisition by Oracle (NYSE: ORCL).
“As I learned more about UserTesting and how companies benefit from its solution, I knew this was a great opportunity with a company that is changing how companies get and use feedback to build exceptional experiences,” said Russo. “I look forward to making a meaningful contribution to what is an already impressive organization, and I look forward to working with my fellow board members to take UserTesting through its next phase of growth.”
“We are pleased to have Cindy and Shannon as the newest board members and look forward to their deep experience in finance and executive leadership,” said Andy MacMillan, CEO of UserTesting. “They both have impressive professional backgrounds from the public company and private company environments. The timing couldn’t be any better to have them join our board and help guide us as we continue our expansion to bring human insights to more companies around the globe.”
Russo and Nash join Tatyana Mamut as independent directors on UserTesting’s board. Investors Andrew Braccia from Accel Partners, and Alex Wong from Topiary Capital also serve on the board of directors alongside UserTesting Founder Darrell Benatar and UserTesting CEO Andy MacMillan.
About UserTesting
UserTesting enables every organization to deliver the best customer experience powered by human insight. With UserTesting’s on-demand Human Insight Platform, companies across industries make accurate customer-first decisions at every level, at the speed business demands. With UserTesting, product teams, marketers, digital, and customer experience executives, designers and UX researchers confidently and quickly create the right experiences for all target audiences, increasing brand loyalty and revenue. UserTesting customers include more than half of the world’s top brands. UserTesting is headquartered in San Francisco, CA. To learn more, visit www.usertesting.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005388/en/
Contact information
UserTesting, Inc.
Chris Halcon
415-699-0553
chalcon@usertesting.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom